Karen Krok

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★

Ran Reshef, Saran Vardhanabhuti, Marlise R. Luskin et al. · American Journal of Transplantation · 2011 · 216 citations · Full text

Transplantation, Autoimmune Disease, Immunosuppressive Therapy +12

Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database

David S. Goldberg, Karen Krok, Sachin Batra et al. · Gastroenterology · 2014 · 135 citations · Full text

Hepatology, Solid Organ Transplantation, Liver Physiology +9

Single‐center outcomes of combined heart and liver transplantation in the failing Fontan

Benjamin D’Souza, Stephanie Fuller, Lacey P. Gleason et al. · Clinical Transplantation · 2016 · 80 citations